Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Omnicom Group Inc. (OMC) vs Revvity Inc (RVTY) Price & Performance

Omnicom Group Inc.Trade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

Omnicom Group Inc. vs Revvity Inc — how do they compare? Omnicom Group Inc. trades at $79.2 (market cap $22.58B), while Revvity Inc trades at $110.67 (market cap $12.33B). The key difference: Omnicom Group Inc. is the larger of the two by market cap, and Omnicom Group Inc. pays the higher dividend (4.04%). Which is the better fit depends on your goals.

OMCRVTY
Market Cap
$22.58B$12.33B
Sector
MediaTechnology
52-Week High
$85.80$117.75
52-Week Low
$67.27$82.26
Enterprise Value
$29.80B$14.82B
Dividend Yield
4.04%0.25%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Omnicom Group Inc.

Omnicom Group (OMC) trades at $79.21, down 3.08% today, with a bullish technical signal from moving averages. The company reported mixed Q1 2026 earnings, beating expectations with $1.90 EPS versus $1.82 expected, but Q4 2025 missed at $2.59 versus $2.72. Revenue growth is strong, reaching $17.27 billion in 2025, though net income was negative $54.50 million due to elevated taxes. Analyst consensus is mixed with 32% buy ratings and a $105.75 price target, representing significant upside. Recent news highlights major client wins including IBM's global media account and partnerships with Netflix and Disney.

OMC presents a value opportunity with a low P/E of 12.16 and P/S of 0.96, trading below analyst targets. The advertising holding company benefits from AI platform expansion and strategic partnerships, but faces margin pressure and intense competition. Near-term catalysts include Q2 2026 earnings on July 28, 2026, where the company must deliver on the expected $2.58 EPS to maintain investor confidence amid current bearish sentiment.

Revvity Inc

RVTY trades at $106.44, down 3.37% today, with a bullish technical outlook despite near-term weakness. The company maintains stable revenue around $2.9B with consistent earnings beats, though valuation multiples appear elevated with a P/E of 51. Recent AI product launches and FDA clearances demonstrate innovation in life sciences and diagnostics. Analyst consensus remains positive with a $111.43 price target and no sell ratings among 29 covering firms.

The stock presents a growth opportunity with strong analyst support and technological innovation, but faces risks from margin pressure and China market exposure. Current levels near support at $105 offer potential entry, though the high P/E requires sustained earnings growth to justify valuation. Upcoming Q2 earnings on August 4, 2026 will be critical for near-term direction.

Returns comparison

Trailing returns across standard periods

About Omnicom Group Inc.

Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.

Read more on OMC

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY